


IN THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) Pharmaceutical or diagnostic composition comprising one or more active substances wherein the one or more active substance is/are selected from a group consisting of:


- (a) active substances with a structure according to formula I-1 to I-9




Formula I-1




Formula I-2




Formula I-3




Formula I-4




Formula I-5




Formula I-6



Formula I-7




Formula I-8




Formula I-9

wherein X in formula I-2 and I-3 is H, OH, NH₂ or a halogen atom and X₁ and X₂ in formula I-4 are any heteroatom;

- (b) active substances with a structure according to formula II-1 or II-2




Formula II-1




Formula II-2


- (c) active substances with a structure according to formula III-1 to III-6




Formula III-1




Formula III-2




Formula III-3



Formula III-4




Formula III-5




Formula III-6

wherein X in formula III-1 and X₁ and X₂ in formula III-5 are H, OH, NH₂ or a halogen atom;


- (d) active substances with a structure according to formula IV-1 to IV-6




Formula IV-1




Formula IV-2




Formula IV-3



Formula IV-4




Formula IV-5




Formula IV-6

X₁ and X₂ in formula IV-6 are selected from H, F, I, Br or Cl, OH or OA, SH or SA, NH₂, NHA₁ or NA₁A₂ or A and wherein A and/or A₁ and A₂ is/are a branched, straight-chain or cyclic alkyl or heteroalkyl group with up to 7 carbon atoms;


- (e) active substances with a structure according to formula V-1 to V-4




Formula V-1



Formula V-2




Formula V-3




Formula V-4

(f) active substances with a structure according to formula VI-1 or VI-2



Formula VI-1




Formula VI-2

wherein R₁ to R₉ and S₁ to S₃ are selected from


- (i) H, OH, NH₂ or a halogen atom;
- (ii) single- or multi-branched or straight-chain alkyl or heteroalkyl groups with one or two rings and up to 10 carbon atoms;
- (iii) cyclic alkyl or heteroalkyl groups with 1 or 2 rings or aryl or heteroaryl groups with up to 10 carbon atoms each.

2. (Currently Amended) Pharmaceutical The pharmaceutical or diagnostic composition according to claim 1, wherein the halogen atoms are selected from [[a]] the group consisting of I, Cl, Br [[or]] and F.
3. (Currently Amended) Pharmaceutical The pharmaceutical or diagnostic composition according to claim 1 or 2, wherein the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 1, 2, 3 or 4 heteroatoms each.
4. (Currently Amended) Pharmaceutical The pharmaceutical or diagnostic composition according to any-of claim[[s 1 to]] 3, wherein the heteroatoms are selected from a group consisting of N, O, [[or]] and S.
5. (Currently Amended) Pharmaceutical The pharmaceutical or diagnostic composition according to any-of claim[[s]] 1 to-4, wherein the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 1, 2, 3 or 4 substituents each.


6. (Currently Amended) **Pharmaceutical** The pharmaceutical or diagnostic composition according to claim 5, wherein the substituents are selected from a group consisting of Cl, F, Br [[or]] and I.
7. (Currently Amended) **Pharmaceutical** The pharmaceutical or diagnostic composition according to any of claim[[s]] 1-to-6, wherein R₁ and R₂, R₂ and R₃, R₃ and R₄, R₄ and R₅, R₅ and R₆, R₆ and R₇, R₇ and R₈ and/or R₈ and R₉ are bridged via further atoms.
8. (Currently Amended) **Pharmaceutical** The pharmaceutical or diagnostic composition according to any of claim[[s]] 1 to-6, wherein the active substance with a structure according to formula I-5 or I-7 is selected from:




Anthraquinone



1,8-Dihydroxy-antraquinone (Dantron)




1,8-Dihydroxy-10H-anthracene-9-one




1,8-Dihydroxy-3-methyl-10H-anthracene-9-one

(Dithranol/ Anthralin)


(Chrysarobin)



1,2,5,8-Tetrahydroxy-antraquinone




4-[2-(1-Amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracene-2-sulfonyl)-ethyl]-N-propyl-benzenesulfoneamide; and




2-Amino-benzoic acid-6-(1-amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracene-2-yloxy)-hexyl-ester.


9. (Original) Pharmaceutical or diagnostic composition according to any of claim[[s]] 1 to 6, wherein the active substance with a structure according to formula I-1 is selected from:




(1-Methyl-1*H*-perimidine-2-yl)-methanol




2-(1H-Imidazole-4-yl)-1H-perimidine




1-Ethyl-1*H*-perimidine




1*H*,3*H*-Perimidine-2-thione




2-Pyridine-3-yl-1*H*-perimidine




1,2-Dimethyl-1*H*-perimidine




4-(1*H*-Perimidine-2-yl)-benzonitrile



2-*p*-Tolyl-1*H*-perimidine




3-(1H-Perimidine-2-yl)-phenylamine; and




2-Pyridin-4-yl-2,3-dihydro-1H-perimidine₁

10. (Currently Amended) Pharmaceutical The pharmaceutical or diagnostic composition according to any of claim[[s]] 1 to 6, wherein the active substance with a structure according to formula I-2 is




8-Fluoro-1,2-dimethyl-4,5-dihydro-pyrrolo[3,2,1-ij]quinoline-6-one.


11. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical or diagnostic composition according to any of claim[[s]] 1 to 6, wherein the active substance with a structure according to formula I-4 has the following formula:




12. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical or diagnostic composition according to claim 11, wherein the active substance is selected from




Phenoxazine-3-one




1,9-Dimethyl-phenoxazine-3-one




7-Amino-1,9-dimethyl-phenoxazine-3-one




7-Hydroxy-1,9-Dimethyl-phenoxazine-3-one




7-Amino-8-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one
(alpha-amino-orcein)




8-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one
(alpha-hydroxy-orcein)




7-Amino-2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one
(beta-amino-orcein)




7-Amino-2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxyazine-3-one
(gamma-amino-orcein)




2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxyazine-3-one
(beta-hydroxy-orcein)



2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxyazine-3-one
(gamma-hydroxy-orcein)




beta-amino-orceimine; and




gamma-amino-orceimine_a


13. (Currently Amended) **Pharmaceutical** The pharmaceutical or diagnostic composition according to any of claim[[s]] 1 to 7, wherein the active substance with a structure according to formula II-2 is selected from:




N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinolin-2-yl)-*N*-(2-dimethylaminoethyl)-formamide




N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-*N*-(2-dimethylaminoethyl)-acetamide




7-Oxo-2-(2-piperidin-1-yl-ethylamino)-6,7-dihydro-thiazolo[4,5-*f*]quinoline-8-carbonitrile




N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-*N*-(3-dimethylamino-propyl)-formamide




N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-acetamide




2-(3-Dimethylamino-propylamino)-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile




2-[(2-Diethylamino-ethyl)-ethyl-amino]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile



2-Amino-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile



2-[4-(3-Hydroxy-propyl)-piperazine-1-yl]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile; and



2-[Benzyl-(2-dimethylamino-ethyl)-amino]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile.

14. (Currently Amended) Diagnostic The diagnostic composition according to any of claim 1 to 13, wherein the active substance or at least one of the active substances is labeled, preferably radioactive labeled.
15. (Cancel)
16. (Currently Amended) Pharmaceutical The pharmaceutical or diagnostic composition according to any of claim[[s]] 1 to 14 or use according to claim 15, wherein the pharmaceutical or diagnostic composition furthermore comprises one or more pharmaceutically acceptable carriers, diluents or excipients.
17. (Currently Amended) Method A method for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases comprising administering a pharmaceutical or a diagnostic composition according to any of claim[[s]] 1 to 14 to a subject.
18. (Currently Amended) Method The method according to claim 17, wherein the subject is a human being.
19. (Currently Amended) Use or The method according to any of claims 15 to 18 claim

- 17, wherein the neurodegenerative disorder is selected from a group consisting of Alzheimer's disease, Parkinson's syndrome and polyglutamine diseases.
20. (Currently Amended) Use or The method according to claim 19, wherein the Parkinson's syndrome encompasses idiopathic Parkinson's disease as well as atypical Parkinson's syndromes associated with protein aggregation; and the polyglutamine diseases encompass Huntington's chorea, spinocerebellar ataxias of types 1, 2, 3, 6, 7 and 17, dentatorubral pallidoluysian atrophy as well as spinobulbar muscular atrophy (Kennedy syndrome).
21. (Currently Amended) Use or The method according to any of claims 15 to 18 claim 17, wherein the amyloid disease is selected from: Hereditary and non-hereditary prion diseases (kuru, fatal familial insomnia, Gerstmann-Straussler-Scheinker syndrome, Creutzfeld-Jacob disease, new variant of Creutzfeld-Jacob disease), dementia with Lewy bodies, primary systemic amyloidosis, secondary systemic amyloidosis with deposits of serum amyloid A, senile systemic amyloidosis, familial amyloid polyneuropathy types I and III, familial nonneuropathic amyloidosis, familial British dementia, hereditary cerebral amyloid angiopathy, hemodialysis-associated amyloidosis, familial amyloidosis-Finnish type, diabetes mellitus type II, hereditary renal amyloidosis, injection amyloidosis with deposits of insulin, medullary carcinoma of the thyroid with deposits of calcitonin, atrial amyloidosis with deposits of ANF, and inclusion body myositis.
22. (New) The diagnostic composition according to claim 14, wherein the labeled active substance is radioactive-labeled.